Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Average Recommendation of "Buy" from Analysts

Key Points

• Palvella Therapeutics, Inc. (NASDAQ:PVLA) has received an average consensus rating of "Buy" from nine research firms, with eight analysts recommending a buy and one providing a strong buy rating.
• The average one-year price target for Palvella Therapeutics stock among brokerages is $47.50, reflecting positive sentiment regarding its future performance.
• In the 4th quarter, several institutional investors significantly increased their stakes in Palvella Therapeutics, contributing to institutional ownership of 40.11% of the company's stock.

Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) has earned an average rating of "Buy" from the nine ratings firms that are covering the firm, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $47.50.

PVLA has been the topic of a number of analyst reports. HC Wainwright reissued a "buy" rating and issued a $38.00 price target on shares of Palvella Therapeutics in a research report on Wednesday, April 30th. Canaccord Genuity Group lowered their price target on Palvella Therapeutics from $53.00 to $52.00 and set a "buy" rating on the stock in a report on Friday, May 16th. Truist Financial started coverage on shares of Palvella Therapeutics in a report on Monday, July 21st. They issued a "buy" rating and a $56.00 price objective on the stock. Finally, Chardan Capital started coverage on Palvella Therapeutics in a research report on Wednesday, April 9th. They set a "buy" rating and a $50.00 target price on the stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Clio Asset Management LLC purchased a new position in Palvella Therapeutics during the 2nd quarter valued at approximately $2,063,000. Goldman Sachs Group Inc. purchased a new position in shares of Palvella Therapeutics in the first quarter valued at $533,000. Woodline Partners LP purchased a new stake in Palvella Therapeutics during the first quarter valued at $5,435,000. Millennium Management LLC bought a new position in Palvella Therapeutics during the first quarter valued at $7,553,000. Finally, AWM Investment Company Inc. purchased a new position in shares of Palvella Therapeutics in the 1st quarter worth $1,943,000. Hedge funds and other institutional investors own 40.11% of the company's stock.

Palvella Therapeutics Trading Up 0.6%

Shares of PVLA traded up $0.24 during mid-day trading on Monday, reaching $37.68. The company's stock had a trading volume of 29,682 shares, compared to its average volume of 92,955. Palvella Therapeutics has a 52 week low of $11.17 and a 52 week high of $40.50. The company's fifty day moving average price is $26.46 and its two-hundred day moving average price is $23.03. The stock has a market cap of $416.74 million, a PE ratio of -3.11 and a beta of -0.11.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.74) earnings per share for the quarter, topping the consensus estimate of ($3.40) by $2.66. Research analysts anticipate that Palvella Therapeutics will post -3.69 EPS for the current year.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.